Related Experiment Videos

Ultrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity

Insights

Adriamycin, an anti-tumor drug, causes significant muscle injury beyond the heart. This study reveals Adriamycin-induced damage in diaphragm and gastrocnemius muscles, correlating with drug concentration.

Area of Science:

  • Pharmacology
  • Toxicology
  • Muscle Biology

Background:

  • Adriamycin (doxorubicin) is a widely used chemotherapy agent with known cardiotoxicity.
  • The precise mechanisms and extent of Adriamycin's effects on non-cardiac muscles are not fully understood.

Purpose of the Study:

  • To investigate the impact of Adriamycin on mouse heart, diaphragm, and gastrocnemius muscle.
  • To compare the ultrastructural damage and Adriamycin concentration across these tissues.

Main Methods:

  • Mice were administered intraperitoneal Adriamycin (20 mg/kg).
  • Cardiac and muscle tissues were analyzed for ultrastructural changes 4 days post-injection.
  • Adriamycin pharmacokinetics and tissue concentrations were determined.

Main Results:

  • Adriamycin induced characteristic cardiac lesions (vacuolation, edema, mitochondrial degeneration).
  • Diaphragm muscle exhibited severe myocyte damage, while gastrocnemius showed increased lipid droplets in red fibers.
  • Tissue Adriamycin levels correlated with the observed myocyte damage (diaphragm > heart > gastrocnemius).

Conclusions:

  • Adriamycin causes significant injury to non-cardiac muscles, mirroring cardiac damage patterns.
  • The severity of Adriamycin-induced myocyte damage is dependent on tissue drug concentration.

Related Concept Videos